Pfizer to add Wyeth directors to board

A regulatory filing made yesterday reveals more juicy details about the Pfizer-Wyeth deal: Pfizer will add two Wyeth directors to its board, the Associated Press reports, and if Wyeth backs out of the deal, it would have to pay a breakup fee of up to $2 billion. As you know, Pfizer's breakup fee is more than double that, at $4.5 billion. Report

Suggested Articles

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.

After a jury ordered Gilead's Kite Pharma to pay $752 million for CAR-T patent infringement, BMS is asking for punitive damages in that amount, too.